Target Entity: Gufic Philippines Inc. (or such other name as may be approved by the Securities and Exchange Commission, Philippines)
Type of Deal: 100% subsidiary incorporation with equity subscription
Stake/Capacity: The Company proposes to hold approximately 99.99% of the equity share capital of the proposed subsidiary. The balance equity shareholding will be held by the directors of the proposed subsidiary in accordance with applicable Philippine laws.
Deal Value: Investment of up to USD 250,000 (United States Dollars Two Hundred Fifty Thousand only), or its equivalent amount in Philippine Peso.
Funding Source: Cash consideration through subscription to equity share capital
Financial Impact: Not disclosed in the document
Timeline: The entity is proposed to be incorporated within 12 months, subject to completion of applicable statutory and regulatory formalities.
Strategic Rationale: The proposed subsidiary will undertake marketing, sale, distribution and other allied activities in relation to the Company's pharmaceutical products in the Philippines. It will facilitate the expansion of the Company's business and presence in the Philippines, including holding and managing Intellectual Property Rights in the Philippines.
Approval Status: Board-approved on August 14, 2026. Subject to completion of applicable statutory and regulatory formalities including:
Incorporation/registration with the Securities and Exchange Commission (SEC), Philippines
Applicable pharmaceutical regulatory approvals/licences and registrations
Compliance with applicable foreign exchange / overseas investment regulations in India
Reference Regulation: SEBI Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
